A randomized study of endobronchial valves for advanced emphysema

Area of Science:

• Pulmonary Medicine
• Interventional Pulmonology
• Respiratory Disease Treatment

Background:

• Advanced emphysema causes pulmonary hyperinflation, impacting lung function and exercise.
• Endobronchial valves (EBVs) reduce lobar volume by allowing one-way air escape, potentially improving outcomes.

Purpose of the Study:

• To compare the safety and efficacy of EBV therapy versus standard medical care in patients with heterogeneous emphysema.

Main Methods:

• A randomized trial involving 321 patients with heterogeneous emphysema.
• Patients were assigned to either EBV therapy or standard medical care.
• Efficacy assessed by changes in forced expiratory volume in 1 second (FEV1) and 6-minute walk test; safety evaluated by complication rates.

Main Results:

• EBV therapy showed a significant improvement in FEV1 (6.8% difference) and 6-minute walk test compared to standard care at 6 months.
• At 12 months, the complication rate was higher in the EBV group (10.3% vs. 4.6%).
• EBV group experienced increased rates of COPD exacerbations requiring hospitalization (7.9% vs. 1.1%) and hemoptysis (6.1% vs. 0%) within 90 days.

Conclusions:

• Endobronchial valve treatment offers modest improvements in lung function, exercise tolerance, and symptoms for advanced heterogeneous emphysema.
• The benefits come with an increased risk of COPD exacerbations, pneumonia, and hemoptysis post-implantation.
• Treatment response may be associated with greater emphysema heterogeneity and fissure completeness.